Neoadjuvant chemotherapy reduces the treatment-free interval after first-line treatment in patients with advanced ovarian cancer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Neoadjuvant chemotherapy reduces the treatment-free interval after first-line treatment in patients with advanced ovarian cancer. / Ekmann-Gade, Anne Weng; Hogdall, Claus Kim; Engelholm, Svend Aage; Fago-Olsen, Carsten Lindberg.
I: Anticancer Research, Bind 40, Nr. 5, 2020, s. 2765-2770.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Neoadjuvant chemotherapy reduces the treatment-free interval after first-line treatment in patients with advanced ovarian cancer
AU - Ekmann-Gade, Anne Weng
AU - Hogdall, Claus Kim
AU - Engelholm, Svend Aage
AU - Fago-Olsen, Carsten Lindberg
PY - 2020
Y1 - 2020
N2 - Background/Aim: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC). Patients and Methods: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity. Results: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005). Conclusion: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy.
AB - Background/Aim: The aim of the study was to compare platinum resistance and treatment-free interval (TFI) following treatment with neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) or primary debulking surgery (PDS) in women with advanced epithelial ovarian cancer (EOC). Patients and Methods: The study included patients diagnosed with primary EOC, stage IIIC or IV, between 2005 and 2013. Patients were grouped according to first-line treatment (PDS vs. NACT-IDS). Date of second-line treatment initiation was used to evaluate platinum sensitivity. Results: The study population included 521 patients, of which 371 (71%) and 150 (29%) underwent PDS and NACT-IDS, respectively. We found no difference in platinum resistance between groups. Platinum-sensitive patients treated with NACT-IDS had a shorter median TFI (372 vs. 497 days, p=0.042). Similarly, patients with no residual tumor after IDS had a shorter median TFI (280 vs. 302 days, p=0.005). Conclusion: NACT-IDS may shorten the TFI after first-line platinum-based chemotherapy.
KW - Neoadjuvant chemotherapy
KW - Ovarian cancer
KW - Platinum resistance
KW - Treatmentfree interval
U2 - 10.21873/anticanres.14248
DO - 10.21873/anticanres.14248
M3 - Journal article
C2 - 32366422
AN - SCOPUS:85084276374
VL - 40
SP - 2765
EP - 2770
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5
ER -
ID: 255842380